Towards Healthcare
Targeted Drugs for Allergic Diseases Market to Lead USD 30.22 Bn by 2034

Targeted Drugs for Allergic Diseases Market

Based on market forecasts, the targeted drugs for allergic diseases sector will expand from USD 13.96 billion in 2024 to USD 30.22 billion by 2034, experiencing a CAGR of 8.06%. The targeted drugs for allergic diseases market is growing due to rising cases of allergies across the globe. North America is dominating due to a high demand for research in developing targeted drugs.

  • Last Updated: 28 October 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

About The Author

Rohan Patil is a seasoned market research professional with over 5 years of focused experience in the healthcare sector, bringing deep domain expertise, strategic foresight, and analytical precision to every project he undertakes.

He began his journey with Precedence Research, where he played a pivotal role in developing high-impact healthcare market reports. Today, Rohan leads research initiatives at Towards Healthcare, while also contributing to Statifacts, where he supports cross-industry analysis and data-driven storytelling.

Rohan’s core strengths lie in trend analysis and emerging technologies, regulatory monitoring and thought leadership through high-quality report writing. He excels at identifying future-ready opportunities and translating complex data into strategic recommendations. His work spans pharmaceuticals, biotechnology, medical devices, and digital health, assessing everything from market potential and competitive positioning to customer needs and regulatory shifts.

A trusted advisor and a relentless innovator, Rohan continues to push the boundaries of traditional market research, merging scientific rigor with commercial insight to stay ahead in a fast-evolving healthcare landscape.

FAQ's

The targeted drugs for allergic diseases market in 2025 is valued at USD 15.08 billion and is projected to climb to USD 30.22 billion by 2034, with a CAGR of 8.06% over the forecast period.

North America is currently leading the targeted drugs for allergic diseases market share by 40% due to the high number of people suffering from one or more allergies.

Some key players include Sanofi S.A., Amgen Inc., Kyowa Kirin Co. Ltd., AstraZeneca plc, Biogen Inc., etc.

Key trends include a rise in demand for personalized medicine, growing research, and gene and cell therapies.

The majority of allergy medications take effect in 30 to 2 hours, whereas nasal sprays take a few days, and allergy shots can take months.

Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, PIB, CDC.